Cognitive Indicators of Preclinical Behavioral Variant Frontotemporal Dementia in MAPT Carriers.
Adult
Aged
Attention
/ physiology
Cohort Studies
Cross-Sectional Studies
Executive Function
/ physiology
Family
Female
Frontotemporal Dementia
/ complications
Heterozygote
Humans
Male
Memory
/ physiology
Memory Disorders
/ etiology
Middle Aged
Prodromal Symptoms
Reaction Time
/ physiology
Social Perception
tau Proteins
/ genetics
Cognition disorders
Frontotemporal dementia
Frontotemporal lobar degeneration
MAPT protein
Neurodegenerative hereditary disease
Tauopathy
Journal
Journal of the International Neuropsychological Society : JINS
ISSN: 1469-7661
Titre abrégé: J Int Neuropsychol Soc
Pays: England
ID NLM: 9503760
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
pubmed:
22
11
2018
medline:
29
4
2020
entrez:
22
11
2018
Statut:
ppublish
Résumé
The cognitive indicators of preclinical behavioral variant Frontotemporal Dementia (bvFTD) have not been identified. To investigate these indicators, we compared cross-sectional performance on a range of cognitive measures in 12 carriers of pathogenic MAPT mutations not meeting diagnostic criteria for bvFTD (i.e., preclinical) versus 32 demographically-matched familial non-carriers (n = 44). Studying preclinical carriers offers a rare glimpse into emergent disease, environmentally and genetically contextualized through comparison to familial controls. Evaluating personnel blinded to carrier status administered a standardized neuropsychological battery assessing attention, speed, executive function, language, memory, spatial ability, and social cognition. Results from mixed effect modeling were corrected for multiplicity of comparison by the false discovery rate method, and results were considered significant at p < .05. To control for potential interfamilial variation arising from enrollment of six families, family was treated as a random effect, while carrier status, age, gender, and education were treated as fixed effects. Group differences were detected in 17 of 31 cognitive scores and spanned all domains except spatial ability. As hypothesized, carriers performed worse on specific measures of executive function, and social cognition, but also on measures of attention, speed, semantic processing, and memory storage and retrieval. Most notably, group differences arose on measures of memory storage, challenging long-standing ideas about the absence of amnestic features on neuropsychological testing in early bvFTD. Current findings provide important and clinically relevant information about specific measures that may be sensitive to early bvFTD, and advance understanding of neurocognitive changes that occur early in the disease. (JINS, 2019, 25, 184-194).
Identifiants
pubmed: 30458895
pii: S1355617718001005
doi: 10.1017/S1355617718001005
pmc: PMC6374161
mid: NIHMS1510207
doi:
Substances chimiques
MAPT protein, human
0
tau Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
184-194Subventions
Organisme : NINDS NIH HHS
ID : U24 NS095871
Pays : United States
Organisme : NIA NIH HHS
ID : K01 AG051348
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000040
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS076837
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG053760
Pays : United States
Organisme : NCRR NIH HHS
ID : UL1 RR024156
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Références
Arch Neurol. 2008 Apr;65(4):460-4
pubmed: 18413467
Parkinsonism Relat Disord. 2003 Jun;9(5):265-70
pubmed: 12781592
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
Brain. 1999 Apr;122 ( Pt 4):741-56
pubmed: 10219785
Alzheimers Res Ther. 2011 Nov 11;3(6):32
pubmed: 22078663
Neuropsychol Rev. 2008 Mar;18(1):91-102
pubmed: 18311522
Lancet Neurol. 2005 Nov;4(11):771-80
pubmed: 16239184
J Neurol Neurosurg Psychiatry. 1995 May;58(5):590-7
pubmed: 7745409
Parkinsonism Relat Disord. 2010 Jul;16(6):404-8
pubmed: 20452812
Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19 Suppl 1:S3-6
pubmed: 16317256
J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1607-10
pubmed: 15489396
Brain Pathol. 1998 Apr;8(2):387-402
pubmed: 9546295
J Clin Exp Neuropsychol. 1990 Aug;12(4):485-501
pubmed: 1698809
Neuropsychology. 2007 Jan;21(1):20-30
pubmed: 17201527
Br J Psychiatry. 2002 Feb;180:140-3
pubmed: 11823324
Neuron. 2003 Apr 10;38(1):127-33
pubmed: 12691670
Arch Neurol. 2008 Feb;65(2):249-55
pubmed: 18268196
Neurology. 2016 Jul 26;87(4):384-91
pubmed: 27358337
Biochim Biophys Acta. 2005 Jan 3;1739(2-3):331-54
pubmed: 15615650
Neurology. 2010 Feb 9;74(6):472-9
pubmed: 20142613
Neuropsychologia. 2006;44(6):950-8
pubmed: 16198378
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Neurology. 1998 Dec;51(6):1546-54
pubmed: 9855500
J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):23-8
pubmed: 23154124
Br J Psychiatry. 1982 Jun;140:566-72
pubmed: 7104545
Neuropathol Appl Neurobiol. 2015 Feb;41(1):24-46
pubmed: 25556536
Alzheimer Dis Assoc Disord. 2009 Apr-Jun;23(2):91-101
pubmed: 19474567
Neurology. 1994 Oct;44(10):1878-84
pubmed: 7936241
Lancet Neurol. 2015 Mar;14(3):253-62
pubmed: 25662776
Ann Neurol. 1999 Oct;46(4):617-26
pubmed: 10514099
Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):S14-8
pubmed: 18090417
Brain. 2015 Oct;138(Pt 10):3100-9
pubmed: 26297556
Neuron. 1998 Nov;21(5):955-8
pubmed: 9856453
Neurology. 2001 Jun;56(11 Suppl 4):S6-10
pubmed: 11402143